益盛药业(002566) - 2019 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was CNY 240,548,305.91, representing a year-on-year increase of 6.16%[7] - Net profit attributable to shareholders of the listed company was CNY 15,261,150.82, up 10.21% year-on-year[7] - Basic earnings per share for the reporting period were CNY 0.0461, an increase of 10.29% compared to the same period last year[7] - Total operating revenue for the current period reached ¥240,548,305.91, an increase of 6.9% compared to ¥226,591,334.39 in the previous period[38] - Total operating costs amounted to ¥218,189,592.71, up from ¥206,650,280.90, reflecting a rise of 5.8%[38] - Operating profit decreased to ¥18,543,599.22 from ¥20,419,563.27, a decline of 9.2%[39] - Net profit for the current period was ¥15,131,185.24, down 8.7% from ¥16,584,006.69 in the previous period[39] - The net profit attributable to the parent company was CNY 55,313,112.65, an increase from CNY 53,129,794.87, showing a growth of approximately 4.1%[48] - Basic and diluted earnings per share were both CNY 0.1671, up from CNY 0.1605 in the previous period, representing an increase of about 4.1%[48] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,540,074,543.43, a decrease of 0.51% compared to the end of the previous year[7] - Total current assets amounted to CNY 2,020,811,110.30, slightly up from CNY 2,014,562,591.55 in the previous period[29] - Total non-current assets decreased to CNY 519,263,433.13 from CNY 538,538,586.44, with fixed assets at CNY 414,493,453.93, down from CNY 437,564,163.19[29] - Total liabilities decreased to CNY 506,246,163.32 from CNY 587,494,366.01, with current liabilities at CNY 459,077,665.38, down from CNY 542,215,902.60[30] - Owner's equity increased to CNY 2,033,828,380.11 from CNY 1,965,606,811.98, with retained earnings rising to CNY 645,149,564.50 from CNY 589,836,451.85[31] - Short-term borrowings decreased to CNY 350,000,000.00 from CNY 430,000,000.00, indicating a reduction in debt[34] - Long-term borrowings increased to CNY 13,020,000.00 from CNY 10,470,000.00, suggesting a strategic move to finance long-term projects[35] Cash Flow - Net cash flow from operating activities decreased significantly by 69.99% to CNY 8,406,884.56[7] - Operating cash flow increased by 39.26% to ¥128,646,977.15 from ¥92,381,953.78, mainly due to reduced purchasing expenses[19] - The cash flow from operating activities was CNY 841,840,854.43, compared to CNY 838,704,254.90 in the previous period, showing a slight increase[54] - The total cash inflow from operating activities increased to ¥701,293,856.49 from ¥670,703,586.11 year-on-year[59] - The company reported a net cash outflow from investing activities of ¥15,296,426.17, compared to a net outflow of ¥43,365,425.14 in the same period last year[56] - Cash inflow from financing activities was ¥322,550,000.00, while cash outflow was ¥413,388,686.33, leading to a net cash outflow of ¥90,838,686.33[56] Shareholder Information - The company reported a total of 21,915 common shareholders at the end of the reporting period[11] - The largest shareholder, Zhang Yisheng, holds 39.08% of the shares, totaling 129,348,530 shares[11] - The company plans to address the issue of shareholding representation by reducing the shares held by certain shareholders in a manner that minimizes market impact[14] - The company aims to resolve the shareholding representation issue promptly while protecting the interests of minority investors[14] Government Subsidies and Expenses - The company received government subsidies amounting to CNY 6,485,858.51 during the reporting period[8] - Research and development expenses rose to ¥7,187,456.00, an increase of 11.3% compared to ¥6,455,227.73[38] - Sales expenses increased to ¥128,943,551.63, up 5.3% from ¥121,771,529.54[38] - Tax expenses increased significantly to ¥4,259,740.01 from ¥2,585,892.18, a rise of 64.7%[38] - The company reported a credit impairment loss of ¥6,292,297.70, indicating potential challenges in asset quality[39] - Tax expenses for the period were CNY 12,332,735.80, slightly down from CNY 12,530,169.57, indicating a decrease of about 1.6%[47] Inventory and Receivables - Cash and cash equivalents increased to CNY 33,395,694.64 from CNY 28,207,006.00, while accounts receivable rose to CNY 194,061,234.95 from CNY 173,942,860.37[33] - Inventory levels remained stable at CNY 1,387,558,592.18, compared to CNY 1,376,696,766.62 in the previous period[33] - Prepayments rose by 112.35% to ¥40,815,469.60 from ¥19,220,882.94, primarily due to increased advance payments for Han Shen cosmetics[19]